Last Week in Biomedicine

Every Tuesday, we break down 10 of the most significant biopharma stories and buzzworthy clinical trial breakthroughs from the previous week. The podcast highlights major Phase 2 and Phase 3 trial results, breakthrough therapies, biotech innovations, FDA updates, and emerging treatments shaping the future of medicine. From obesity and cancer to autoimmune disease, neurodegeneration, cardiovascular disease, diabetes, and rare genetic disorders, each episode delivers a fast, accessible look at the data, discoveries, and therapies driving the next generation of healthcare.

Last Week in Biomedicine is a health podcast hosted by TrialBreaks, with 17 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

TrialBreaks hosts Last Week in Biomedicine, a health show with 17 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Last Week in Biomedicine

  Last Week in Biomedicine | Jun 29–Jul 3 | Part 2 of 2: Baby Pompe Disease Trial, DLBCL Combo Win

  Jul 9, 202637 min

  Part 2 covers three more standout stories from the same week: a Phase 3 trial that gives babies with a devastating enzyme disease a fighting chance, a first-of-its-kind cell therapy approved to make bone-marrow transplants safer, and a new lymphoma combination that could give aggressive-blood-cancer patients another option after other therapies fail. In Part 2 we cover: 4. Sanofi — Nexviazyme (avalglucosidase alfa) for infantile-onset Pompe disease (Phase 3) 5. Orca Bio — Tregzi (allogeneic regulatory T-cell immunotherapy) for adults with blood cancers undergoing matched-donor bone-marrow transplant (FDA approval) 6. Genmab / AbbVie — Epkinly (epcoritamab) plus lenalidomide for relapsed or refractory diffuse large B-cell lymphoma (Phase 3) What could this mean for patients? The Sanofi Baby-COMET result is the most emotionally consequential story of the week. Infantile-onset Pompe disease is usually fatal in a baby's first year without treatment, and a Phase 3 trial hitting every primary and secondary endpoint means more infants may reach toddlerhood breathing on their own — an outcome that was unimaginable a generation ago. Catch Part 1 if you missed it. Subscribe at TrialBreaks.com. #biomedicine #clinicaltrials #science #Pompedisease #enzymereplacement #rarediseases #genetherapy #celltherapy #bonemarrowtransplant #GVHD #hematology #lymphoma #DLBCL #bispecificantibody #immunotherapy #oncology

  ListenShow Notes
• 

  Last Week in Biomedicine

  Last Week in Biomedicine | Jun 29–Jul 3 | Part 1 of 2: CRISPR for Toddlers, KRAS Lung Cancer Win

  Jul 7, 202644 min

  CRISPR gene editing crossed a major line this week: the FDA now allows Casgevy — the first CRISPR therapy of any kind — for children as young as 2 with sickle cell disease, meaning we can potentially prevent a lifetime of pain crises and organ damage instead of treating them after the fact. Part 1 also digs into a rare kind of trial where a new lung cancer drug takes on the already-approved competition, and a New England Journal of Medicine paper on the first oral pill for a form of childhood dwarfism. In Part 1 we cover: 1. Vertex Pharmaceuticals / CRISPR Therapeutics — Casgevy (exagamglogene autotemcel) for sickle cell disease and transfusion-dependent beta thalassemia in children ages 2 and up (FDA approval — label expansion) 2. Roche / Genentech — divarasib for KRAS G12C-mutant non-small cell lung cancer (Phase 3) 3. BridgeBio Pharma / Kyowa Kirin — oral infigratinib for achondroplasia in children (Phase 3, published in NEJM) What could this mean for patients? Casgevy in toddlers is the story with the biggest potential ripple effect. Sickle cell disease starts hurting kids in infancy, so treating a 2-year-old before repeated strokes and organ damage sets in could redefine what growing up with sickle cell looks like. It's also a proof point that CRISPR-based cures can be delivered safely in very young children — a green light for other pediatric gene-editing programs in development. Part 2 drops Thursday morning. Subscribe at TrialBreaks.com. #biomedicine #clinicaltrials #science #CRISPR #genetherapy #sicklecell #lungcancer #KRAS #achondroplasia #oncology #rarediseases #pediatrics #hematology #NEJM #immunotherapy

  ListenShow Notes
• 

  Last Week in Biomedicine

  Last Week in Biomedicine | June 22–26 | Part 2 of 2: Thyroid Eye Disease, ADHD + Anxiety, Skyrizi Kids

  Jul 2, 202641 min

  Part 2 covers a new drug for the bulging-eye autoimmune disease, the first Phase 3 ADHD trial designed for patients who also have anxiety, and a major pediatric expansion for a top-selling psoriasis biologic. In Part 2 we cover: 4. Viridian Therapeutics — Lumvoa (veligrotug) for thyroid eye disease, active and chronic (FDA approval) 5. Otsuka Pharmaceutical — centanafadine for adult ADHD with comorbid anxiety (Phase 3b) 6. AbbVie — Skyrizi (risankizumab) for pediatric plaque psoriasis and psoriatic arthritis (FDA approval) The biggest story in Part 2: Lumvoa is only the second IGF-1 receptor antibody ever approved for thyroid eye disease, but it has a much broader label than its predecessor — covering both the active early form and the chronic long-standing form that affects far more patients. For people who've lived with bulging eyes and double vision for years and were told nothing could help, this approval is genuinely new ground. Catch Part 1 if you missed it. Subscribe at TrialBreaks.com. #biomedicine #clinicaltrials #science #ophthalmology #thyroideyedisease #ADHD #anxiety #mentalhealth #dermatology #psoriasis #pediatrics #immunology #FDAapproval #autoimmune #IL23

  ListenShow Notes
• 

  Last Week in Biomedicine

  Last Week in Biomedicine | June 22–26 | Part 1 of 2: LSD Depression Phase 3, Trodelvy TNBC Approval

  Jun 30, 202637 min

  This week, an LSD-based therapy hit its main goal in a Phase 3 depression trial — and two huge breast cancer approvals landed at the FDA on the same week. In Part 1 we cover: 1. Definium Therapeutics — DT120 (LSD-based orally disintegrating tablet) for major depressive disorder (Phase 3) 2. Gilead Sciences / Merck — Trodelvy (sacituzumab govitecan) ± Keytruda for first-line PD-L1+ metastatic triple-negative breast cancer (FDA approval) 3. Pfizer — Ibrance (palbociclib) + trastuzumab ± pertuzumab for HR+/HER2+ metastatic breast cancer maintenance (FDA approval based on Phase 3 PATINA) The biggest story: Definium's Emerge trial showed a single dose of DT120 produced rapid relief from major depression that lasted weeks — the first time an LSD-based therapy has cleared a pivotal Phase 3 in this disease. After years of mixed results for psilocybin and MDMA programs, this readout could reopenthe door for psychedelic medicines and give patients who don't respond to standard antidepressants a fundamentally new option. Part 2 drops Thursday morning. Subscribe at TrialBreaks.com. #biomedicine #clinicaltrials #science #psychiatry #depression #psychedelics#oncology #breastcancer #immunotherapy #ADC #FDAapproval #neuroscience#womenshealth #cancerresearch

  ListenShow Notes
• 

  Last Week in Biomedicine

  Last Week in Biomedicine | June 14–20 | Part 2 of 2: Mezigdomide Myeloma, HCM Heart Drug

  Jun 25, 202625 min

  Part 2 of our week of June 14–20, 2026 wrap-up covers a new molecular glue for relapsed multiple myeloma that cut disease progression by half, a heart drug that may finally work forboth forms of hypertrophic cardiomyopathy, and a new combination regimen poised to upgrade the first-line standard of care in myelofibrosis. In Part 2 we cover:4. Bristol Myers Squibb — Mezigdomide for relapsed/refractory multiple myeloma (Phase 3) 5. Edgewise Therapeutics — EDG-7500 for obstructive and non-obstructive hypertrophic cardiomyopathy (Phase 2) 6. Karyopharm Therapeutics / Menarini — Selinexor plus ruxolitinib for first-line myelofibrosis (Phase 3) The most patient-impactful of these three is probably the Edgewise heart drug. Hypertrophic cardiomyopathy — a too-thick heart muscle that makes it hard to pump blood — is the most common inherited heart disease, but today'smyosin-inhibitor drugs only help people whose blood flow is physically blocked. EDG-7500 showed clear improvements in both the obstructive and non-obstructive forms, potentially more than doubling the number of patients who could benefit. Catch Part 1 if you missed it. Subscribe at TrialBreaks.com. #biomedicine #clinicaltrials #science #oncology #cardiology #hematology#myeloma #HCM #cardiomyopathy #myelofibrosis #CELMoD #sarcomere#drugdevelopment #precisionmedicine

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.